Talaris Therapeutics
Cell Processing Facility & Corporate Office
570 S. Preston St.
Louisville, KY 40202
United States
Website: https://talaristx.com/
Email: info@talaristx.com
About Talaris Therapeutics
Talaris Therapeutics is developing a breakthrough, one-time cell therapy to enable patients who receive a living donor kidney transplant to no longer require lifelong immunosuppression, without rejecting their donated organ.
Achieving durable, drug-free immune tolerance to a donated organ has been referred to as a “Holy Grail” of organ transplant. In a ground-breaking, phase 2 study conducted between 2008 - 2016, our lead therapy, FCR001, enabled 70% of patients to be weaned off all immunosuppression within 12 months of their kidney transplant. No tolerized patient has had to resume immunosuppression. We have followed these patients for an average of almost five years since their transplant, and the longest for over ten years. Our single-dose cell therapy has also shown the potential to induce durable remission of certain types of severe auto-immune diseases, and to benefit other solid organ transplant patients. Talaris has announced a $100M private financing from leading life sciences investors and has initiated a Phase 3 pivotal trial of our therapy in living donor kidney transplant patients. We also expect to initiate two Phase 2 trials of our therapy in additional indications in 2020. Our cell processing facility and most of our operations are based in Louisville, KY, and we also have a corporate office in Boston, MA.
47 articles with Talaris Therapeutics
-
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Talaris Therapeutics, Inc. announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
-
Talaris Therapeutics Announces Changes to Board of Directors
5/17/2022
Talaris Therapeutics, Inc. announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company’s Board of Directors.
-
Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update
5/12/2022
Talaris Therapeutics, Inc. reported financial results for the three-month period ended March 31, 2022, and provided an update on its business.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
-
Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001
4/6/2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), today shared new data on COVID-19 outcomes among living donor kidney transplant (LDKT) patients treated in the Company’s Phase 2 trial of investigational cell therapy product FCR001 (NCT00497926).
-
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences - Mar 22, 2022
3/22/2022
Talaris Therapeutics, Inc. announced that members of its senior management team will participate at the following investor conferences:
-
Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results
3/17/2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today reported financial results for the quarter and year ended December 31, 2021, and provided an update on its business.
-
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/11/2022
Talaris Therapeutics, Inc. announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.
-
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.
-
Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
1/4/2022
Talaris Therapeutics, Inc. announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.
-
Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index
12/20/2021
Talaris Therapeutics, Inc. today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), active prior to market open today.
-
Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant Analysis
12/14/2021
Talaris Therapeutics, Inc. today presented a new analysis of HLA mismatching between donors and recipients participating in the Company’s Phase 2 trial in living donor kidney transplant (LDKT).
-
As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.
-
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma
11/30/2021
Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, announced the initiation of the company’s Phase 2 FREEDOM-3 trial in diffuse cutaneous systemic sclerosis, a severe form of the rare autoimmune disease scleroderma.
-
Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
11/12/2021
Talaris Therapeutics, Inc. (Nasdaq: TALS), today reported financial results for the three- and nine-month periods ended September 30, 2021, and provided an update on its business.
-
Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences
11/8/2021
Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that members of its senior management team will participate at the following investor conferences.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting
11/4/2021
Talaris Therapeutics, Inc., a late-clinical stage cell therapy company, provided the first clinical update on its Phase 3 FREEDOM-1 study in living donor kidney transplant recipients, and also separately presented a clinical update and additional data from ongoing follow-up of its fully-enrolled Phase 2 study in LDKT recipients at the 2021 American Society of Nephrology meeting.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look.